GSC-linked lncRNA GIHCG as a new therapeutic target in glioblastoma
Official title: Unlocking the Potential of the GSC-Associated lncRNA GIHCG as a Therapeutic Target in Glioblastoma
Funded at University of New Haven · NIH-11401067 · Data updated 2026-11-12
Aims to understand and block a brain cancer RNA that helps glioblastoma stem cells grow, with the goal of improving survival for patients with glioblastoma.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of New Haven NIH-funded |
| Lab location | 1 site (West Haven, United States) |
| Project start | September 1, 2025 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $129,400 |
| NIH project number | 5R16NS147984-02 |
| Project ID | NIH-11401067 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be glioblastoma patients whose disease could be connected to glioblastoma stem cell biology or who could contribute tumor samples for research.
✕Less likely to help
Patients without tumors driven by glioblastoma stem cells or without access to related samples may see limited direct benefit.
What this research studies
This project focuses on glioblastoma, a deadly brain tumor, and explores how a specific long noncoding RNA called GIHCG helps cancer stem cells survive and spread. Researchers will use genetic tools to remove GIHCG in glioblastoma stem cells and study the effects on growth and movement. The work also aims to see if high GIHCG levels correlate with worse outcomes, suggesting it could be a biomarker and target for therapy. Findings could pave the way for new RNA-based treatments that disable these stubborn cancer cells. The study is anchored at the University of New Haven with a plan spanning several years.
Why it matters
Potential benefit: If successful, patients with glioblastoma could benefit from new RNA-targeted therapies that slow tumor growth and improve outcomes.
How similar studies have gone: Previous work shows that targeting cancer stem cell–related lncRNAs can reduce tumor growth in models, supporting this approach as promising.
Where this research is happening
-
University of New Haven
West Haven, United States Active
Researchers
- Principal investigator: Hazra, Rasmani — University of New Haven
- Study coordinator: Hazra, Rasmani
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.